Rubius Therapeutics (RUBY) Reports Q3 Loss of $0.59

Rubius Therapeutics (NASDAQ: RUBY) reported Q3 EPS of ($0.59), versus ($0.42) reported last year.

For earnings history and earnings-related data on Rubius Therapeutics (RUBY) click here.

You May Also Be Interested In

• Abercrombie & Fitch (ANF) Tops Q2 EPS by $2.19, Offers Guidance
• JinkoSolar (JKS) Misses Q2 EPS by RMB 7.10, Misses on Revenue
• PMGC Holdings drops Arizona acquisition after due diligence review